OrbiMed’s Myovant Sciences Ltd. MYOV Stock Holding History

OrbiMed’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50,000	Closed	-$703K	–	163
2020 Q3	$703K	Buy	+50,000	New	+$930K	0.01%	141

Other funds holding MYOV

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

OrbiMed's MYOV Position: Q4 2020 in Review

OrbiMed sold out of Myovant Sciences Ltd. (MYOV) in Q4 2020, closing a stake of 364,500 shares — an estimated $5.12M sold.

OrbiMed first reported a position in MYOV in Q3 2020 and held it in 1 quarter. The position peaked at $5.12M in Q3 2020. 105 funds tracked by Wall St. Rank hold MYOV as of Q4 2020.

OrbiMed reported no remaining Myovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 364,500 Myovant Sciences Ltd. shares in Q4 2020, an estimated $5.12M.
OrbiMed first reported a position in Myovant Sciences Ltd. in Q3 2020 and held it in 1 quarter.
OrbiMed's Myovant Sciences Ltd. position peaked at $5.12M in Q3 2020.
105 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.